In most instances the increase in KRASG12X VAF in blood preceded determination of clinical progression. Longitudinal assessment of ctDNA indicates that some patients with RAS-addicted tumors undergo a molecular response on treatment with the SHP2 inhibitor RMC-4630....
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial. Sai-Hong Ignatius Ou, University of California Irvine, Irvine, CA, USA SHP2是由PTPN11基因编码的非受体蛋白酪氨酸磷酸酶,负责催化磷酸酪氨酸的去...
characterized by an increase in CD8+T cell infiltrates and selective depletion of pro-tumorigenic M2 macrophages.In this study, we evaluated pharmacodynamic biomarkers in blood and tumors from patients in the RMC-4630 phase I monotherapy clinical trial (NCT 03634982) by using flow cytometry and immu...
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signalingdoi:10.1016/s0959-8049(20)31089-3J. Bendell...
A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trialdoi:10.1016/j.jtho.2019.12.041S.I. OuM. KoczywasS. UlahannanP. JanneJ. Pacheco...
The SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: Preliminary evaluation of a first-in-man phase 1 clinical trial. Sai-Hong Ignatius Ou, University of California Irvine, Irvine, CA, USA SHP2是由PTPN11基因编码的非受体蛋白酪氨酸磷酸酶,负责催化磷酸酪氨酸的去...